About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Elecoglipron
- Company
- AstraZeneca
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 12 recruiting
Efficacy results: Not yet reported
12 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Oct 22, 2026
Find a Clinical Trial Near Me
See recruiting studies for Elecoglipron and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT06797401
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
Not yet reported Ribocure Pharmaceuticals AB 120 participants Est. completion 2027-09-30 4 sites Stand-aloneOther conditions: DyslipidemiasView official trial listing → -
Recruiting NCT NCT07610837
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Not yet reported AstraZeneca 104 participants Est. completion 2027-07-07 21 sitesOther conditions: Liver Fibrosis, Hepatic CirrhosisView official trial listing → -
Recruiting NCT NCT07662044
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Not yet reported AstraZeneca 800 participants Est. completion 2028-07-14 149 sites Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07662109
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Not yet reported AstraZeneca 2000 participants Est. completion 2028-07-05 272 sites Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07662135
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Not yet reported AstraZeneca 900 participants Est. completion 2028-07-13 186 sites Stand-aloneType 2 diabetesChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT07662213
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Not yet reported AstraZeneca 1200 participants Est. completion 2028-05-23 209 sites Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07664553
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Not yet reported AstraZeneca 600 participants Est. completion 2028-05-23 132 sites Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07667803
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Not yet reported AstraZeneca 4500 participants Est. completion 2029-07-30 325 sites Stand-aloneOther conditions: Weight ManagementView official trial listing → -
Recruiting NCT NCT07723833
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
Not yet reported AstraZeneca 152 participants Est. completion 2026-11-18 2 sites Stand-aloneOther conditions: Healthy ParticipantsView official trial listing → -
Recruiting NCT NCT07753993
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Not yet reported AstraZeneca 7000 participants Est. completion 2030-10-04 715 sites Stand-aloneChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT07761117
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Not yet reported AstraZeneca 6950 participants Est. completion 2029-09-03 679 sites Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT07775404
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
Not yet reported AstraZeneca 351 participants Est. completion 2028-04-13 49 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Completed NCT NCT01451593
Neuroprotection With Phenytoin in Optic Neuritis
Not yet reported University College, London 92 participants Est. completion 2015-03 2 sitesOther conditions: Optic Neuritis, Multiple SclerosisView official trial listing → -
Withdrawn NCT NCT01702415
Zoledronic Acid in Cystic Fibrosis
Not yet reported Papworth Hospital NHS Foundation Trust Est. completion 2015-12 1 site Stand-aloneOther conditions: Cystic FibrosisView official trial listing → -
Completed NCT NCT03404063
Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)
Not yet reported, Not yet reported John Paul II Hospital, Krakow 105 participants Est. completion 2021-03-31 2 sites Stand-aloneCardiovascular diseaseView official trial listing → -
Completed NCT NCT04632706
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
Not yet reported MedinCell S.A 24 participants Est. completion 2021-03-09 1 site Stand-aloneOther conditions: Covid19View official trial listing → -
Completed NCT NCT04701983
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Not yet reported Sanofi 1127 participants Est. completion 2025-08-27 248 sites Stand-aloneOther conditions: Chronic Obstructive Pulmonary DiseaseView official trial listing → -
Completed NCT NCT04751487
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Not yet reported Sanofi 1234 participants Est. completion 2025-08-28 238 sites Stand-aloneOther conditions: Chronic Obstructive Pulmonary DiseaseView official trial listing → -
Completed NCT NCT05095077
Effects of Single Dose Tadalafil on Urethral and Anal Closure Function
Not yet reported University Hospital Bispebjerg and Frederiksberg 24 participants Est. completion 2022-01-01 1 siteOther conditions: Urinary Incontinence,Stress, Fecal IncontinenceView official trial listing → -
Completed NCT NCT05305560
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
Not yet reported MedinCell S.A 400 participants Est. completion 2022-10-13 1 site Stand-aloneOther conditions: COVID-19View official trial listing → -
Completed NCT NCT06208306
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Not yet reported Sanofi 669 participants Est. completion 2026-09-10 223 sites Stand-aloneOther conditions: Chronic Obstructive Pulmonary DiseaseView official trial listing → -
Completed NCT NCT06579092
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
Not yet reported AstraZeneca 310 participants Est. completion 2025-11-21 62 sites Stand-aloneOther conditions: Obesity or OverweightView official trial listing → -
Status unknown NCT NCT06593145
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Not yet reported FamiCordTx 6 participants Est. completion 2025-06 2 sites Stand-aloneOther conditions: Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL), Large B-cell LymphomaView official trial listing → -
Active, not recruiting NCT NCT06649266
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
Not yet reported Ribocure Pharmaceuticals AB 14 participants Est. completion 2027-08 2 sitesOther conditions: Chronic Hepatitis DView official trial listing → -
Completed NCT NCT06717074
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease
Not yet reported Ribocure Pharmaceuticals AB 30 participants Est. completion 2026-04-29 1 siteCardiovascular diseaseView official trial listing → -
Active, not recruiting NCT NCT07534592
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
Not yet reported AstraZeneca 48 participants Est. completion 2026-10-01 2 sites Stand-aloneOther conditions: Healthy ParticipantsView official trial listing → -
Active, not recruiting NCT NCT07587788
RBD5044 in Chinese Participants With Hypertriglyceridemia
Not yet reported Ribotek Biopharmaceuticals (Shandong) Co., Ltd 40 participants Est. completion 2027-03 7 sites Stand-aloneOther conditions: HypertriglyceridemiaView official trial listing → -
Not yet recruiting NCT NCT07850453
Vortosiran for VTE Prevention
Not yet reported Ribocure Pharmaceuticals AB 150 participants Est. completion 2028-05 30 sitesOther conditions: Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)View official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Elecoglipron, Active IMP
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.